SEK 2.76
(-8.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 12.27 Million SEK | 49.96% |
2022 | 8.18 Million SEK | -22.02% |
2021 | 10.49 Million SEK | -37.81% |
2020 | 16.88 Million SEK | -19.09% |
2019 | 20.86 Million SEK | 366.76% |
2018 | 4.46 Million SEK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 FY | 12.27 Million SEK | 49.96% |
2023 Q2 | 7.34 Million SEK | 8.08% |
2023 Q4 | 12.27 Million SEK | -20.6% |
2023 Q3 | 15.45 Million SEK | 110.45% |
2023 Q1 | 6.79 Million SEK | -16.97% |
2022 Q4 | 8.18 Million SEK | 30.63% |
2022 Q3 | 6.26 Million SEK | -19.16% |
2022 Q2 | 7.75 Million SEK | -10.27% |
2022 Q1 | 8.63 Million SEK | -17.7% |
2021 Q1 | 16.04 Million SEK | 0.0% |
2021 Q4 | 10.49 Million SEK | -13.14% |
2021 Q3 | 12.08 Million SEK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AcuCort AB | 58.5 Million SEK | 79.02% |
AlzeCure Pharma AB (publ) | 32 Million SEK | 61.642% |
BioGaia AB (publ) | 2.33 Billion SEK | 99.474% |
Enzymatica AB (publ) | 125.91 Million SEK | 90.251% |
Enorama Pharma AB (publ) | 34.38 Million SEK | 64.301% |
Gabather AB (publ) | 2.93 Million SEK | -317.943% |
Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | 83.213% |
Moberg Pharma AB (publ) | 634.73 Million SEK | 98.066% |
Nanexa AB (publ) | 132.25 Million SEK | 90.719% |
Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | 86.492% |
Orexo AB (publ) | 786.6 Million SEK | 98.439% |
Probi AB (publ) | 1.55 Billion SEK | 99.208% |
Swedencare AB (publ) | 9.52 Billion SEK | 99.871% |
Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.983% |
Toleranzia AB | 160.42 Million SEK | 92.349% |
Vivesto AB | 355.87 Million SEK | 96.551% |